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Abstract
Biomarker host genetic signatures are considered key tools for improved early diagnosis of tuberculosis (TB) disease
(development). The analysis of gene expression changes based on a limited number of genes or single study designs,
however, may not be sufficient for the identification of universal diagnostic biomarker profiles. Here we propose that
biological pathway and process based analyses from multiple data sets may be more relevant for identification of key
pathways in TB pathogenesis, and may reveal novel candidate diagnostic TB biomarkers. A number of independent
genome-wide gene expression studies have recently been performed to study expression of biomarkers for TB disease. We
have integrated the results from these independent studies and performed pathway- as well as biological process-based
analysis on the total data set. Interestingly, IFNa/b signalling is not the single dominant pathway in the analysis of the total
dataset, but combined, functional, analysis of biomarkers suggests a strong dominant role for myeloid cell involvement in
inflammation.
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Introduction
Biomarkers are defined as: ‘‘characteristics that can be
objectively measured and evaluated as an indicator of a normal
biological process, a pathogenic process, or a (pharmacologic)
response to a therapeutic intervention’’ [1]. Biomarkers could be
of great significance in the battle against tuberculosis (TB),
especially in the development of better diagnostics and new
vaccines [2]. A number of new TB vaccine candidates have been
developed over the past decade and many of them are currently in
early stage clinical development. The next major step will be to
test the protective efficacy of these new candidates, which will
present a major challenge because of the nature of TB infection
and its progression to disease: in most individuals, infection with
Mycobacterium tuberculosis (Mtb) results in latent infection that can
persist for decades, with active disease development in about 3–
10% of infected individuals, mostly within the first 2 years post
infection [3,4]. The low incidence rates of TB disease require large
and lengthy clinical vaccine efficacy trials in TB endemic areas to
achieve the statistical power needed to demonstrate vaccine
induced protection against disease development.
As an alternative to using clinical endpoints, scientists are
urgently searching for biomarkers that predict whether individuals
are (long-term) protected or at (increased) risk for disease
development. Such biomarkers would allow assessment of vaccine
efficacy at earlier stages and with smaller groups of individuals,
and allow comparison of multiple TB vaccine candidates in
efficacy studies. Thus, the demonstration of TB vaccine efficacy
and biomarker efficacy are both of eminent importance. Such
biomarkers would also facilitate licensure of new efficacious TB
vaccines in different age groups (infants, children, adults) as well as
ethnically and geographically different populations (particularly
Africa and Asia) without having to perform further large scale
efficacy testing.
Biomarker Challenges
Identification of biomarkers of protection against TB disease is
challenging because there is no gold standard of infection or
protection. Our understanding of what is strictly required for host
protection from TB disease is incomplete, which hampers vaccine
development [2,2,5]. Moreover, validation of biomarkers against
clinical endpoints is difficult because in TB clinical endpoints
cannot always be clearly defined. For the curative response to
treatment time to sputum conversion is frequently used, but for
protection against disease development no gold standard clinical
definition is available. In infant BCG vaccination studies,
protection has been defined as known exposure to TB within the
household without the development of disease within 2 years
following exposure [6]. This definition is probably suitable for
infants that experience most exposure within the household,
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however, for most (adult) people it is difficult to trace exposure to
TB and thus disease-free time post exposure [7]; moreover, adults
may more often be re-exposed during the 2 year follow up period,
confounding estimations of disease incidence. Clinical endpoints
should be comparable among studies to allow ranking and
prioritization of biomarkers [2]. An additional complexity is that
new candidate TB vaccines are quite different by nature, e.g. live
vaccines compared to subunit vaccines or priming compared to
boosting vaccines, which each may induce protection in a different
manner and may thus require different sets of biomarkers to
evaluate vaccine induced protection [2].
Next to biomarkers of protection against TB disease develop-
ment, also biomarkers predicting disease risk are extremely
important in vaccine trials: these may identify individuals at risk
at an early stage and thus help to significantly shorten follow-up
times and numbers. Biomarkers of early TB disease development
may be easier to identify since in contrast to protection, TB disease
can be demonstrated using microbiological diagnosis (bacterial
staining or culture, GeneXpert MTB/RIF), X-ray or made highly
likely based on clinical manifestations. To identify biomarkers of
disease-risk, patients can be compared to various other groups,
including those with latent TB, treated TB patients or patients
with other inflammatory or infectious diseases. Early identification
of individuals at risk of developing TB disease will help reducing
the occurrence of contagious pulmonary TB and thus limit disease
transmission.
Biomarkers will thus be critical tools in the battle against TB.
However, a number of issues need to be taken into consideration
when comparing biomarker studies. First, geographic or ethnic
variations may significantly impact on immune responses towards
TB due to a variety of factors which include: host genetic factors;
the presence of environmental microbes like helminths or HIV
[8,9] (Table 1); exposure to/infection with immunomodulatory
(environmental) non-tuberculous mycobacteria; previous BCG
vaccination; Mtb exposure intensity and frequency; reinfection
rates; Mtb strain heterogeneity etc. Concomitant HIV infection
may predominantly affect biomarkers derived from the CD4+ T
cell compartment. In addition, metabolic conditions may influence
immunity and biomarker signatures following vaccination or
infection. For example, obesity and type 2 diabetes mellitus (T2D)
both result in continuous low-grade systemic inflammation,
including cytokine and chemokine production, switching of
macrophage subsets from anti-inflammatory Mf2 to pro-inflam-
matory Mf1 [10,11]. The significance of T2D for TB has emerged
from epidemiological data and prompted WHO to initiate
combined care for TB and T2D [12–15]. Patients with T2D
have a 3-fold increased risk to develop TB disease, and
achievement of negative sputum cultures as a measure of
treatment success takes longer as compared to non-T2D TB
patients [12–15]. Also low body mass indexes and malnutrition are
significant risk factors for the development of TB disease,
indicating that nutritional status is an important factor for TB
disease, which may significantly affect measurable biomarker
profiles [14,16].
Secondly, the type of material used for biomarker determination
may greatly determine the type of biomarkers that can be
detected. Whole blood contains large numbers of neutrophils,
which are present at a very low frequency in isolated PBMCs, and
which seem to be cells that express promising TB biomarkers [17–
20]. On the other hand, the strong signal from these large
numbers of neutrophils in whole blood may obscure highly
relevant and specific gene expression profiles from smaller
populations, e.g. T-cells, B-cells, monocytes or other relatively
rare populations. Furthermore, it is recognized that the isolation of
cells from whole blood may alter their gene expression profiles,
which is further enhanced if blood processing is delayed for several
hours [21–23]. Therefore, biomarkers should preferably be
analysed on the same type of material over different studies and
processing time should be standardized to reduce variation
(Table 1) [22–25]. These differences in cell populations may be
reflected in differential expression of particular biomarkers, and
thus not only reflect the response to TB but also indicate changes
in comorbidities. Finally, biomarkers for different forms of disease
may be different, e.g. pulmonary vs. extrapulmonary TB, partly
because samples obtained from peripheral blood, sputum or
pleural fluid have different cellular compositions.
TB biomarkers and other diseases
The use of biomarkers to predict TB disease progression (or
ultimately vaccine efficacy or protection) is complicated by the
nature of these markers. Most TB biomarkers or biomarker-
signatures identified so far are indicators of general (intracellular)
infection and subsequent immune activation, rather than highly
specific for TB disease. There is a large overlap with biomarkers
reported in other inflammatory diseases including SLE, sarcoid-
osis, melioidosis and Still’s disease [17,26,27], as well as following
Yellow Fever vaccination [28]. With the exception of sarcoidosis
and melioidosis, most of these diseases can be discriminated rather
easily from TB based on clinical symptoms or examination in
combination with existing diagnostics.
It is unsurprising that TB biomarker profiles overlap signifi-
cantly with other infections and inflammatory conditions, since
most pathways represent genes associated with immune activation
and inflammation. At the cellular level, infection with any
pathogen may trigger activation of innate cells through pattern
recognition receptors (TLRs, NLRs etc.), resulting in upregulation
of markers and cytokines/chemokines irrespective of the exact
nature of the pathogen. Following specific recognition by the
adaptive immune system, this will similarly result in activation of
innate cells, initiating a modular response to eliminate the
Table 1. Factors that may affect TB Biomarkers.
patient age
geographic origin/
ethnicity
environmental exposure (eg environmental
mycobacteria)
previous vaccinations (eg BCG during
childhood)
co-infections (eg HIV, Helminths)
metabolic state (malnutrition, obesity, T2D)
use of immunomodulating drugs (eg immune
suppression)
pathogen strain (eg MDR, Beijing)
route of entrance (eg vaccine vs natural
infection)
site of disease (pulmonary vs extrapulmonary)
time since infection/stage of disease
progression
sample type of sample (eg whole blood, PBMCs, fluid from disease site)
time between collection and
fixation
sample handling (eg isolation procedures, temperature)
doi:10.1371journal.pone.0073230.t001
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invading pathogen. Thus, it is to be anticipated that a large
number of biomarkers should be shared between disease processes
that rely on similar host-module responses.
Global TB Biomarker Signatures
Multiple studies have analysed production of single cytokines or
chemokines, or the expression of cell surface markers at the
protein or mRNA level as biomarkers for TB disease. More
recently, single candidate biomarkers were combined into
multicomponent signatures to increase power and specificity.
Advanced statistical methods were applied to select genes from
(global) transcriptomic datasets and to compile signatures includ-
ing the smallest possible number of genes to retain good predictive
values. Such signatures appear to be more powerful biomarkers
than individual genes or proteins [19,29,30].
Recently, multiple groups have reported global gene expression
analysis in different cohorts of TB patients with active disease
(Table 2). In these studies, signaling through the type I interferon
(Interferon alpha/beta (IFNa/b)) pathway was frequently reported
as important in TB disease, although the molecules identified as
differentially expressed or produced were not identical between all
different cohorts or studies. Because the pathways involved are
clearly related and overlapping, we decided to analyse the TB
biomarker signatures emerging from these genome wide tran-
scriptomic studies as a group, using a ‘‘helicopter’’ perspective by
jointly analyzing data from all published genome wide expression
studies on TB disease to date. A helicopter view over all data may
allow comparative analysis of all available data rather than a
comparison of individual pathways identified by each study. Since
all data are assessed to be equally important the distant view from
the helicopter should allow identification of major players in the
TB disease development. This should help to better characterize
the key processes and pathways involved rather than identifying
markers which might be relatively unique to certain study settings,
determined e.g. by the specific population sampled, time and type
of sampling, and other possible confounders discussed above. We
reasoned that the processes or pathways identified by such an
analysis should be more reliable and generic, and thus may
provide a platform for further TB biomarker exploration and
evaluation in a global context.
Methods
Data input
Over 6 years eight independent genome wide expression studies
have been performed on blood from patients with active TB
disease (Table 2) [17–20,26,29,31,32]. Individuals with active TB
disease were compared to different control populations, including:
patients longitudinally followed during treatment; healthy (infect-
ed) individuals; and patients with other (infectious) diseases
(Table 2). Patients originated from different geographical regions,
including Europe, Asia, Saharan and Sub-Saharan Africa. Gene
expression data were analysed within each study, mostly involving
pathway analysis to determine the most dominant signaling
pathways within that cohort in comparison to their specific
control population. Gene signatures were determined that could
serve as biomarkers to discriminate patients with active TB disease
from the respective control population included. A number of
studies also included pathway ontology analysis to decipher the
potential cell subsets or cellular processes that were most different
between TB disease and control populations.
Here, we combined all genes identified by each of the eight
independent global gene expression studies to discriminate
between patients with active TB disease and controls, into a
single data set, allowing more comprehensive analysis of gene
expression changes during TB disease. All genes identified by each
of the individual studies as differentially expressed between TB
disease and their respective control populations were included in
this analysis. Gating criteria for gene selection were determined by
the individual authors and their selection of genes differentially
expressed in TB disease versus their respective control population
was added into our study, irrespective whether the genes were up
or downregulated. A total gene-set of 409 genes was the result of
combining all 8 individual studies.
Analysis
The total gene-set (409 genes) from all studies mentioned in
Table 2 was analysed functionally using 3 different platforms:
a. Modular analysis: grouping based on similar expression
kinetics over multiple diseases/processes as described by
Chaussabel et al [33]. We have used the updated version of
the modules that is available at: http://www.biir.net/
public_wikis/module_annotation/G2_Trial_8_Modules.
Genes (both formal gene names according to genecards.org
and alternative names as specified in Table S1) were searched
within the modules and indicated in Table S1. Colour coding
was performed based on the name of the modules and thus all
modules named ‘interferon’ or ‘inflammation’ received the
same colour.
b. Molecular interactions: association of genes into ‘integrated
pathway analysis’ (IPA), including analysis of canonical
pathways involved using IngenuityTM platforms, available
at: www.ingenuity.com. All 409 genes were inserted into
Ingenuity integrated pathway analysis and network generation
was performed to search for defined molecular interactions
between genes (gene products). Results were visualized as
networks (Figure 1) and ranked as canonical pathways
involved (Table 3).
c. Biological pathways: Gene Set Enrichment Analysis (GSEA)
[34]. Genes were tested against the ‘Molecular signature
Database’ (MsigDB, http://www.broad.mit.edu/gsea/
msigdb) C2 collection (4850 gene sets). All 409 genes were
compared to the database of 4850 known datasets to search
for the datasets with the highest overlap in gene-expression
profiles and thereby to identify processes or diseases that
mimic our set of genes derived from TB disease patients
(Table 4).
Results and Discussion
Pathway analysis of state-of-the art Biomarker data
The combination of individual markers from these 8 indepen-
dent studies (table 2) [17–20,26,29,31,32], yielded 409 genes
associated with TB disease, 39 of which were identified by more
than 1 independent study. All 409 genes are summarized in
Table S1 and include a reference to the original studies that have
identified these genes as well as the number of studies that
identified that particular gene. All genes identified by more than
one study are separately analysed in Figure 3.
Modular analysis. Categorizing individual genes is a useful
tool to obtain insights in relative representations of functional
groups in the dataset. A number of independent studies have used
the modular classification described by Damian Chaussabel [33],
which is based on the assumption that the probability for multiple
transcripts to follow a complex pattern of expression across dozens
of conditions only by chance is low and such sets of genes should
A Helicopter Perspective on TB Biomarkers
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therefore constitute coherent and biologically meaningful tran-
scriptional units. He used microarray based gene expression
profiles from a number of diseases and grouped genes according to
their concordance in expression profiles [33]. Pubmed searches
were done to identify module functional associations, resulting in
rather broad, cell type based allocations in particular as a
consequence of using PBMCs as source material. Conceptually
the modular framework is very elegant and expected to give
insights in processes that are strongly enriched within a gene
expression data set. However, the number of genes that can be
grouped into the modules initially was limited. Recently, a novel
version of these modules was published, which is now based on
Illumina microarray platforms and contains a larger number of
genes (publically available at: http://www.biir.net/public_wikis/
module_annotation/G2_Trial_8_Modules). Also the number of
modules was greatly expanded in this new version compared to the
previous version [33]. All 409 genes in our current data set were
annotated according to the latest version of the modules (web
publication date August 2012) (Table S1). 371/409 (90.7%) genes
in the combined dataset were retrieved and assigned to modules
(Table S1). However, the majority of genes (195/371 or 52.6%)
were allocated to modules without functional assignment (unde-
termined/not determined), resulting in only 176/409 (43.0%) of
genes with a functional classification (Table S1, Figure 2). Two
modules are highly represented in the dataset: 68/176 (36.6%) of
the allocated genes belong to the inflammatory signature and 36/
176 (20.5%) genes belong to the interferon related signature.
Genes identified in more than 1 independent studies also
predominantly represented patterns of inflammation (9/39; 23%)
and interferon related pathways (7/39; 17.9%) (Figure 3).
The modular analysis as described above thus hints towards a
prominent role for inflammation and interferon signaling in TB
disease, as was also described by most individual studies. The
disadvantage of the modular data analysis is the limited relation of
gene sets within a module to specific functional capacities, the
relative lack of sensitivity for small changes in gene expression
profiles, mostly because the data sets used to annotate the modules
were all derived from PBMCs, with their particular cellular
composition, and did not include specialized cell types, or
specifically activated pathways. For example, monocytes and
macrophages only represent a low proportion of PBMCs (5–10%)
and thus specific monocyte activation pathways may not be
recognized by the modular annotation.
Molecular Interactions. Ingenuity based pathway analysis
revealed highly significant overlap with 92 canonical pathways
with p,0.001 and a total of 196 canonical pathways p,0.05. To
select the most important pathways within our dataset we defined
and applied filter criteria on the 92 canonical pathways with the
highest significance. First, pathways were excluded if they were
smaller than 50 genes; secondly, pathways were excluded if fewer
than 10 out of the total of 409 gene dataset mapped in that
pathway; and thirdly, we only considered pathways in which our
genes represented at least 10% of the total gene-set in that
pathway. This resulted in 36 pathways that were significantly
abundant in our data set of 409 genes (Table 3, Figure 2).
Biological pathways. Gene Set Enrichment Analysis
(GSEA) [34] determines whether there is significant overlap or
enrichment of genes in published biological pathways with genes
in a query list. To evaluate the degree of enrichment the GSEA
method calculates an Enrichment score (ES) and False Discovery
Rate (FDR). We tested our set of 409 genes against the Molecular
signature Database C2 collection (4850 gene sets) collected from
various sources such as online pathway databases, publications in
PubMed, and knowledge of domain experts. In the GSEA analysis
230 gene sets were returned with a significant enrichment score
(ES) although only 15 of these gene sets were significant at an FDR
of ,5% (Table 4, Figure 2).
Pathway and process based analysis
TREM1 signaling pathway. The Ingenuity canonical path-
way overlapping the combined dataset with highest significance
level was ‘TREM1 signaling’ (Table 3). Genes that comprise the
TREM1 canonical pathway are depicted in Table 5, in addition
genes identified in our dataset are indicated. The dataset overlaps
with TREM1 signaling directly, but also has significant overlap
with TLR and downstream TLR signalling as well as with effector
Table 2. Information on studies included.
study reference population sample collection # TB patients type of sample
initial,
independent
1 Mistry R, JID, 2007: 195, 357 active TB disease vs healthy infected controls South Africa n = 10 whole blood
2 Jacobsen M, J Mol Med, 2007:
85, 613
active TB disease vs healthy infected controls Germany n= 9 PBMC
3 Berry MP, Nature, 2010: 466, 973 active TB disease vs healthy infected &
uninfected controls vs other inflammatory
disorders
(SLE, Stills, Streptococcus,
Staphylococcus)
United Kingdom
(test), South Africa
(validation)
n = 13, n = 20 whole blood
4 Maertzdorf J, Genes & Immunity,
2011: 12, 15
active TB disease vs healthy infected &
uninfected controls
South Africa n = 33 whole blood
5 Maertzdorf J, PLoS ONE, 2011:
6, e26938
active TB disease vs healthy infected &
uninfected controls
The Gambia n= 46 whole blood
6 Maertzdorf J, PNAS, 2012:
109, 7853
active TB disease vs heatlhy infected &
uninfected controls & sarcoidosis
Germany n= 8 whole blood
7 Cliff J, JID, 2013: 207, 18 active TB disease over time during treatment South Africa n = 27, n = 9 whole blood
8 Ottenhoff TH, PLOS ONE, 2012:
7, e45839
active TB disease over time during treatment
vs healthy controls
Indonesia n = 23 PBMC
doi:10.1371journal.pone.0073230.t002
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cytokines secreted following TREM1 activation. This is a novel
finding, not detected in any of the individual published studies.
TREM1 or ‘Triggering receptor expressed on myeloid cells 1’ is a
member of the Ig superfamily and is predominantly expressed on
myeloid cells. Cell surface expression of TREM1 is increased upon
cellular activation, e.g. by LPS and other microbial products [35].
Expression of TREM1 results in amplification of neutrophil- and
monocyte-mediated inflammatory responses, by increased cyto-
kine production and upregulation of cell activation markers, as
seen in bacterial and fungal infections. TREM1 signaling
pathways interact with signaling pathways downstream from the
IFNaR1/2 and from TLRs [36,37]. Cross-talk between TREM1
and TLR2 and TLR4 signaling cascades have been demonstrated,
and potentially also other TLR (TLR 3, 5, 7, 8, and 9) and
possibly NLR signaling pathways are influenced by TREM1
signaling [37]. TREM1 and TLR2 signaling pathways can
synergize at the level of cytokine production [37]. TREM1 plays
a crucial role in fine-tuning of the inflammatory response by
amplifying or dampening TLR induced signals, and is known to
tune the septic response in order to facilitate efficient clearance of
the pathogen without damaging the host [36]. The ligand of
TREM1 is currently unknown, although it has been speculated
that it may be expressed on pathogens, thereby directly activating
TREM1 signaling [37]. Peptidoglycans on gram positive bacteria
and endotoxins on gram-negative bacteria are candidate ligands,
and mycobacterial peptidoglycans might also serve as TREM1
ligands. This remains to be determined but would be an
interesting explanation for the increased TREM1 signaling
observed in patients with active TB disease.
A soluble variant of TREM1 has also been identified
(sTREM1). This results from the shedding of cell surface TREM1
by metalloproteinases, and is thought to negatively regulate
TREM receptor signaling through neutralization of the ligands
[35]. In patients with pulmonary TB sTREM1 has been detected
Figure 1. Ingenuity pathway analysis of all genes identified by unbiased methods related to TB disease. All 409 biomarkers were
analysed by integrated pathway analysis using Ingenuity and the most dominant network is depicted here. Signalling pathways were coloured
according to functional classification into myeloid cells, T cells and B cells and type I interferon related genes.
doi:10.1371journal.pone.0073230.g001
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in sputum [38], but levels could not discriminate pulmonary TB
from community acquired pneumonia caused by other pathogens.
In patients with pleural effusions, sTREM1 levels could discrim-
inate infectious, including TB, from non-infectious causes and the
levels of pleural fluid sTREM1 appeared a useful tool to
discriminate Mtb infection from malignancies [39]. An indepen-
dent study on pleural effusions showed a similar increase in
sTREM1 levels in TB effusions compared to non-infectious
effusions [40]. In addition, surface TREM1 was assessed on cells
within the effusions and was undetectable in effusions from
patients with TB pleuritis [40], however cell numbers and cellular
composition were not described. Similarly, in BAL (bronchoalve-
Table 3. Results of Ingenuity pathway analysis.
Ingenuity Canonical Pathways
-log (p-
value) p-value Ratio Overlap with dataset
categorie in table S1 (approximate)
TREM1 Signaling TREM 1 signalling 1,6E01 1,00E-16 3,33E-01 19/57 (33%)
Fcc Rec.-mediated Phagocytosis in Macroph. and Monoc. myeloid cells 1,46E01 2,50E-15 2,32E-01 22/95 (23%)
Mitochondrial Dysfunction mitochondria 1,39E01 1,12E-14 1,85E-01 25/135 (19%)
Pattern Recognition Rec. in Recognition of Bacteria and
Viruses
myeloid cells 1,37E01 1,99E-14 2,21E-01 21/95 (22%)
Macroph., Fibrobl. and Endothelial Cells in Rheumatoid
Arthritis
myeloid cells 1,18E01 1,58E-12 1,06E-01 33/311 (11%)
B Cell Receptor Signaling B cell 9,78E00 1,65E-10 1,36E-01 22/162 (14%)
PI3K Signaling in B Lymphocytes B cell 9,21E00 6,16E-10 1,48E-01 19/128 (15%)
Communication between Innate and Adaptive
Immune Cells
– 8,43E00 3,70E-09 1,61E-01 15/93 (16%)
Dendritic Cell Maturation myeloid cells 8,3E00 5,00E-09 1,09E-01 21/192 (11%)
Systemic Lupus Erythematosus Signaling inflammation 8,17E00 6,76E-09 1,01E-01 23/228 (10%)
IL-8 Signaling inflammation 7,72E00 1,90E-08 1,09E-01 21/192 (11%)
Natural Killer Cell Signaling – 6,76E00 1,73E-07 1,36E-01 15/110 (14%)
Prod. of Nitric Oxide and Reactive Oxygen Species
in Macroph.
myeloid cells 6,5E00 3,16E-07 1,02E-01 19/186 (10%)
NF-kB Signaling inflammation 6,45E00 3,50E-07 1,06E-01 18/170 (11%)
Role of Tissue Factor in Cancer – 6,03E00 9,33E-07 1,28E-01 14/109 (13%)
Erythropoietin Signaling hematopoiesis 5,85E00 1,40E-06 1,49E-01 11/74 (15%)
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis inflammation 5,83E00 1,47E-06 1,4E-01 12/86 (14%)
Toll-like Receptor Signaling myeloid cells 5,79E00 1,62E-06 1,75E-01 10/57 (18%)
IL-3 Signaling hematopoiesis 5,59E00 2,57E-06 1,51E-01 11/73 (15%)
CD28 Signaling in T Helper Cells T cells 5,01E00 9,77E-06 1,07E-01 13/122 (11%)
IL-12 Signaling and Production in Macrophages myeloid cells 4,98E00 1,05E-05 1,02E-01 14/137 (10%)
Chemokine Signaling inflammation 4,92E00 1,20E-05 1,47E-01 10/68 (15%)
FAK Signaling – 4,76E00 1,74E-05 1,12E-01 11/98 (11%)
FLT3 Signaling in Hematopoietic Progenitor Cells hematopoiesis 4,75E00 1,78E-05 1,37E-01 10/73 (14%)
Atherosclerosis Signaling – 4,73E00 1,86E-05 9,92E-02 13/131 (10%)
iCOS-iCOSL Signaling in T Helper Cells T cells 4,73E00 1,86E-05 1,07E-01 12/112 (11%)
Rac Signaling – 4,73E00 1,86E-05 1,03E-01 12/117 (10%)
Apoptosis Signaling – 4,67E00 2,14E-05 1,2E-01 11/92 (12%)
Prolactin Signaling hematopoiesis 4,65E00 2,24E-05 1,3E-01 10/77 (13%)
Pancreatic Adenocarcinoma Signaling – 4,6E00 2,51E-05 1,04E-01 12/115 (10%)
PDGF Signaling – 4,44E00 3,63E-05 1,27E-01 10/79 (13%)
IL-6 Signaling inflammation 4,21E00 6,17E-05 9,84E-02 12/122 (10%)
HGF Signaling hematopoiesis 4,19E00 6,45E-05 1,08E-01 11/102 (11%)
G Beta Gamma Signaling – 3,94E00 1,15E-04 1E-01 10/100 (10%)
Fc Epsilon RI Signaling – 3,81E00 1,54E-04 9,91E-02 11/111 (10%)
T Cell Receptor Signaling T cells 3,62E00 2,39E-04 9,8E-02 10/102 (10%)
IGF-1 Signaling – 3,59E00 2,57E-04 9,8E-02 10/102 (10%)
All canonical pathways significantly associated with the dataset are depicted (p,0.001), after application of the following filter criteria: gene set comprises at least 50
genes, at least 10 genes from dataset are retrieved in gene set and at least 10% of genes from gene set are present in the data set of 409 genes.
doi:10.1371journal.pone.0073230.t003
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olar lavage) cells from patients with pulmonary TB no significant
increase in cell-surface TREM1 expression was observed com-
pared to BAL cells from non-infectious controls, whereas BAL cells
from patients with other pulmonary infections did express
increased TREM1 levels on macrophages and neutrophils [41].
Thus, TREM1 related signaling seems important during active TB
disease; although cellular TREM1 expression levels may not be
changed, levels of soluble sTREM1 are increased at the site of
disease.
Myeloid lineage cells. In addition to TREM1 signaling, a
number of other pathways associated with myeloid cell function or
activation were prominently identified in the Ingenuity analysis
(Table 3). These included: ‘Fcc receptor-mediated phagocytosis in
macrophages and monocytes’; ‘role of pattern recognition
receptors in recognition of bacteria and viruses’; ‘role of
macrophages, fibroblasts and endothelial cells in Rheumatoid
Arthritis’; ‘Dendritic cell maturation’; Production of Nitric Oxide
and reactive oxygen species in macrophages’; ‘Toll-like receptor
signaling’; ‘IL-12 signaling and production in macrophages’. In
Table 3 these are grouped together into a ‘myeloid’ category,
which was then applied to allocate individual genes into functional
categories in Table S1. Increased expression of genes associated
with Toll-like receptor signaling [18,19,26] and Fcc Receptor
signaling [26,29] were previously reported in patients with active
TB disease. Grouping of genes according to the canonical pathway
based groups resulted in categorization of 107 out of the total 409
genes in the dataset. The myeloid signature thus identified is
strong and also more clearly represented than in any of the
individual studies: 56/107 (52.3%) genes that were grouped into
canonical pathways were in the myeloid category, although the
majority overlaps with other categories as well, including TREM1
signaling.
As with the Ingenuity based pathway analysis, most of the
GSEA gene sets we identified represented a myeloid biased gene
signature and an inflammatory immune response. The gene sets
SEKI_INFLAMMATORY_RESPONSE_LPS_UP, ICHIBA_-
GRAFT_VERSUS_HOST_DISEASE_35D_UPICHIBA_GRA-
FT_VERSUS_HOST_DISEASE_D7_UP, JISON_SICKLE_-
CELL_DISEASE_UP and REACTOME_IMMUNE_SYSTEM
overlap with each other and comprise many genes associated
with myeloid cells (Table 4). The dominance of these gene
signatures reflect the findings of the studies the signatures were
derived from. Cliff et al [31], Berry et al [17] and Ottenhoff
et al [32] all highlight an increased myeloid cell inflammatory
responses in active TB patients when compared to controls.
Network analysis revealed a strong contribution of genes
associated with myeloid cells in the most dominant network
(figure 1), however many genes overlapped with more than one
process (Table S1, Figure 1). These comprised signaling pathways
around Akt, MYD88 and the NFkB complex as central players in
the network, indicating an important role for inflammation,
phagocytes and professional antigen presenting cells including
macrophages. Indeed the early microarray studies performed in
TB patients indicated that genes with roles in inflammation and
immunity were most abundantly expressed [18,20,26,32] and
most inflammation related genes differentially expressed were
derived from monocytes [17,19,29,32]. Interestingly, Cliff et al.
speculated that some of the genes specifically upregulated during
TB disease can be expressed by macrophages and DCs but not by
monocytes, and thus may reflect activated APCs, possibly cells
trafficking between lungs and lymphoid tissue via the blood [31].
This could also explain the relatively high myeloid gene expression
observed in TB patients and in particular the involvement of TLR
and Fc receptor induced signaling, since these processes would
normally be expected to occur at the site of disease rather than in
the circulation. The pathways associated with these myeloid cells
point towards a strong role for direct pathogen related processes,
even in the circulation (not the disease site in TB).
T-cells and B-cells. Although the emerged profiles are
dominated by inflammatory and myeloid gene signatures there
was one gene set associated with CD4 T Cell/follicular helper T
cell activation (PICCALUGA_ANGIOIMMUNOBLASTI-
Table 4. Results from GSEA.
GSEA gene expression data sets categorie in table S1 NES FDR q-val SIZE
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS myeloid cells 2,07 0,041 15
REACTOME_GPCR_LIGAND_BINDING myeloid cells 2,08 0,041 18
SEKI_INFLAMMATORY_RESPONSE_LPS_UP inflammation 2,14 0,034 18
SMID_BREAST_CANCER_NORMAL_LIKE_UP inflammation 2,15 0,034 31
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP T cells 2,32 0,041 18
MOSERLE_IFNA_RESPONSE interferon 2,25 0,028 16
LIU_VAV3_PROSTATE_CARCINOGENESIS_UP inflammation 2,16 0,037 16
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP inflammation 2,12 0,032 17
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP myeloid cells 2,08 0,04 15
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP inflammation 2,13 0,033 25
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP inflammation 2,17 0,037 26
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP myeloid cells 2,27 0,04 26
MARKEY_RB1_ACUTE_LOF_UP inflammation 2,52 0,014 39
JISON_SICKLE_CELL_DISEASE_UP inflammation 2,25 0,023 36
REACTOME_IMMUNE_SYSTEM inflammation 2,25 0,034 101
Gene sets with an FDR ,5% were included in this analysis. SIZE indicates the number of genes in both the gene set and the expression dataset. NES the primary result
of the gene set enrichment analysis is the enrichment score (ES), which reflects the degree to which a gene set is overrepresented in a list of genes. Normalizing the
enrichment score (NES) accounts for differences in gene set size and in correlations between gene sets and the expression dataset.
doi:10.1371journal.pone.0073230.t004
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C_LYMPHOMA_UP) [42] (Table 4). CD4 T cells are important
for the control of Mtb infection and TB disease, proliferate and are
activated in response to antigens from M. tuberculosis. It is
possible that these follicular helper T cells are contributing to the
formation of B cell follicles during active TB disease. Studies of
human TB granulomas have identified B cell follicle structures
which may contribute to the immune response in TB, and
activated B cells have been found in granulomas of nonhuman
primates infected with Mtb [43,44].
As expected also canonical pathways associated with B cell
function (as previously reported by [19,31]), T cell function
(previously reported by [31]) and more general inflammation
processes were identified by Ingenuity analysis (Table 3). The
potential functional implications of B cells in TB disease have been
debated for decades, in particular because intracellular pathogens
Figure 2. Functional classification of individual genes identified by gene expression analysis on TB patients. Categories have been
based on combined output from Ingenuity and GSEA software modules and may include multiple canonical pathways or cell processes. Myeloid cells
includes the following canonical pathways: role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis; Fcg Receptor mediated
phagocytosis in macrophages and monocytes; role of pattern recognition receptors in recognition of bacteria and viruses; IL12 signaling and
production in macrophages; Dendritic cell maturation; production of Nitrox Oxide and Reactive Oxygen Species in Macrophages; Toll like receptor
signaling. T cells includes: T cell receptor signaling; CD28 signaling in T helper cells; iCOS-iCOSL signaling in T helper cells. B cells includes: B cell
receptor signaling; PI3K signaling in B lymphocytes. Interferon related pathways include: Interferon signaling, role of jak1, jak2 and tyk2 in interferon
signaling, role of PKR in interferon induction and antiviral response. Inflammation includes: IL-8 signaling; NF-kB signaling; altered T cell and B cell
signaling in Rheumatoid Arthritis; systemic lupus erythematosus signaling; chemokine signaling; IL-6 signaling. TREM1 includes specifically TREM1
signaling and mitochondrial dysfunction also only contains mitochondrial dysfunction. Finally, hematopoiesis includes: erythropoietin signaling; IL-3
signaling; FLT3 signaling in hematopoietic progenitor cells; prolactin signaling; HGF signaling.
doi:10.1371journal.pone.0073230.g002
Figure 3. Genes identified by more than 1 independent study. Genes identified by more than 1 independent global genome-wide gene
expression analysis. Manuscript numbers refer to Table 2. Classification into modules, functional groups according to Ingenuity and GSEA was
performed according to Tables 3 & 4 and identical to Genes identified by more than 1 independent global genome-wide gene expression analysis.
Manuscript numbers refer to Table 2. Classification into modules, functional groups according to Ingenuity and GSEA was performed according to
Tables 3 & 4 and identical to Table S1.
doi:10.1371journal.pone.0073230.g003
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are considered to be sequestered from circulating antibodies.
However, functional significance of B cells in TB disease has been
demonstrated in mouse models: B cell deficient mice appear more
susceptible to TB [45], and Fc-receptors play a role in protection.
Furthermore, in addition to the presence of B cells in human TB
lesions as described above, the expression of human FccR1 is a
consistent and strong component in TB biomarker signatures
[19,29,30]. These observations suggest that B cells may play a
hitherto unappreciated role in immunity in TB. This is further
supported by recent results that suggest that also intracellular
binding of antibody to pathogens can take place via a cytosolic Fc-
receptor called TRIM21 [46,47]. Pathogen bound antibody
triggering of TRIM21 subsequently stimulated transcription factor
pathways including NF-kB, IRF7 and others, resulting in immune
activation and inflammatory signals. This may open up an
interesting new angle for the potential role of B cells and in
particular antibodies in the combat against TB, which should be
explored in more detail. Interestingly, our network based analysis
of genes expressed in peripheral blood from TB patients does
include TRIM21 (Figure 1). Gene expression of TRIM21 was
detected in cohorts of TB patients compared to healthy controls
[19] (Table S1) and was grouped close to Fc Receptors and its
defined signaling molecule IRF7 in the Ingenuity network analysis.
Hematopoiesis. A process which was not expected but
clearly represented in the canonical pathway analysis was
hematopoiesis, represented by ‘Erythropoietin signaling’; ‘IL-3
signaling’; ‘FLT3 signaling in hematopoietic progenitor cells’;
‘prolactin signaling’ and ‘HGF signaling’. This indicates that in the
blood of patients with TB disease active remodeling apparently is
ongoing, either with renewal of hematopoietic cells at a possibly
increased rate compared to non-TB controls or with cells
emerging from the bone marrow and on their way to the site of
inflammation (mostly the lung in TB patients). Recently it has
been demonstrated that Mtb may hijack mesenchymal stem cells
and may survive in the CD271+ stem cells for a long period after
successful treatment of pulmonary TB, hiding from the immune
system [48]. This suggests that stem cells in the bone marrow may
be active players in TB disease, revealing a new cell type involved
in TB pathogenesis. Another interesting link between mycobac-
terial infections and stem cells is the recent observation that
Mycobacterium leprae is capable of reprogramming host gene
expression in adult Schwann cells and induces a dedifferentiation
program towards stem cell like cells (SLC) [49]. These SLC can
Table 5. TREM1 canonical pathway.
identified in study nr:
Akt 5
anti-TREM1 Ab
CASP1
Casp1-Casp5
CASP5
CCL2 8
CCL3
CCL7 8
CD40 4;8
CD83
CD86
CSF2
CXCL3 2
DEFB4A/DEFB4B
EBOV
ERK1/2 5
FCGR2B 5
Flagellin
GRB2
ICAM1
IL10
IL18
IL1B
IL6
IL8 7
IRAK1
ITGA5
ITGAX
ITGB1
JAK2
L-Ala-?-D-Glu-meso-diaminopimelinic acid
LAT2
lipopolysaccharide
lipoteichoic acid
MARV
MARV GP
MPO 2;6
MYD88 4
N-acetylmuramyl-L-alanyl-D-isoglutamine
NFkB (complex)
NLR
NOD2
Pam3-Cys
PLC gamma 5
poly rI:rC-RNA
prostaglandin E2
resiquimod
SIGIRR
ST2
Table 5. Cont.
identified in study nr:
STAT3
STAT5a/b 4
Tlr 4;8;3*
TLR2 4
TLR4 4
TNF
TREM1
TYROBP 3
Genes involved in TREM1 signaling canonical pathway according to Ingenuity
Integrated Pathway analysis. Genes identified in our 409 gene total geneset are
indicated in the right column. * TLR genes include TLR2,4,5,6,7,8 and were
identified by multiple studies, all genes identified count in overlap with
pathway count according to Ingenuity
doi:10.1371journal.pone.0073230.t005
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subsequently redifferentiate into end stage tissue cells, and also
release bacteria onto macrophages locally in tissues [49]. It
remains unknown whether Mtb also possesses the capacity to
reprogram host cells by activating pathways characteristic for
hematopoiesis, but this may be an interesting possibility that fits
with the observed changes in gene expression profiles. Interest-
ingly, the vast majority of genes categorized as ‘hematopoiesis’ is
also associated with several myeloid functions (Table 3).
Type I Interferon Signaling. Berry et al [17] were the first
to describe that Type I interferon signaling was increased in TB
patients. The pathway MOSERLE_IFNA_RESPONSE was
amongst the 15 most significant pathways identified by GSEA in
active TB disease (Table 4). Surprisingly, interferon a/b related
signaling pathways were not amongst the top pathways represent-
ed by our dataset in Ingenuity (Table 3), despite it being detected
with high significance in several individual studies. Interferon
signaling reached statistical significance (p= 0.000026), but was
lost during application of gating criteria, due to the small number
of genes in the pathway (,50) and the small number of genes
overlapping with our dataset (,10). However, because of the
interest in IFNa/b signaling in TB disease, we added a category
IFNa/b to table 3 based on all 3 canonical pathway datasets
related to type I interferon signaling in Ingenuity ‘interferon
signaling’; ‘role of JAK1, JAK2 and TYK2 in interferon signaling’
and ‘role of PKR in interferon induction and antiviral response’.
IFN signaling represented 13/107 (12.1%) genes in our dataset
and was thereby not the most dominant pathway (figure 1,
Table S1). Signaling through IFNa/b seems an important
pathway associated with TB disease in most independent studies,
although many molecules involved in downstream IFNa/b
pathways are not uniquely involved in transmitting signals derived
from IFNa/b receptors but may also be critical components in
other pathways.
Type I interferons are classically known as early response
molecules in the context of viral infections and are well known
immune modulators. Type I interferon signaling in mycobacterial
infections, as shown in progressive leprosy disease, may contribute
to disease pathogenesis or protection, depending on the balance
between IFNa/b and IFNc [50], in which IFNa/b may actively
inhibit IFNc signalling. Interestingly in virus infection models the
IFNa/b response mediated enhanced antiviral activity during
acute infection but exerted strong immunomodulatory effects
during chronic infection [51]. Both TB and leprosy are long term,
chronic infections; in both diseases an increased expression of
IFNb induced genes has been observed, suggesting its potential
involvement in tissue damage and inflammation, and in regulating
adaptive IFNc responses. It may be speculated that patients with
latent Mtb infection have strong IFNc induced responses which
are downregulated by IFNa/b during reactivation from latent to
active TB disease [4,50].
Macrophages or monocytes infected with Mtb produce and
secrete type I interferons [52]. Mtb strains with increased virulence
induce increased IFNA mRNA in lungs of infected mice [53], and
lower local levels of pro-inflammatory cytokine mRNAs (IL-6, IL-
12, TNFa and IFNc). The effect of IFNa/b was further
investigated by administration of IFNa to mice following infection
with Mtb, resulting in increased pulmonary bacterial loads and
reduced survival of the mice [53]. In vitro, addition of type I
interferons to BCG infected macrophages resulted in increased
outgrowth of BCG, suggesting direct effects of type I interferons on
infected cells in favor of the mycobacteria [54]. The increase in
type I interferons and IFNa/b signaling during active TB disease
may therefore reflect IFNa/b production by infected monocytes/
macrophages and facilitate and maintain rather than clear chronic
infection.
Fibrosis. Statistically, using GSEA analysis, the greatest
overlap of our gene-set was observed with the gene set
Figure 4. Schematic representation of events during active TB Disease. Pathway and process based analysis suggests that these processes
are key players in TB disease pathogenesis.
doi:10.1371journal.pone.0073230.g004
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MARKEY_RB1_ACUTE_LOF_UP, a gene set expressed in
fibroblasts [55] (Table 4). Fibroblasts secrete extracellular matrix
molecules, while extracellular matrix destruction is necessary for
the growth and persistence of Mtb: Mtb is a potent inducer of the
metalloproteinases (MMPs) which destroy extracellular matrix
[56]. MMP9 and MMP25 are found among our gene list of 409.
MMP expression is enhanced by G protein coupled receptor
signalling and type 1 interferon – both of which are represented in
our GSEA analysis (REACTOME_GPCR_LIGAND_BINDING
and MOSERLE_IFNA_RESPONSE). MMP9 is the most abun-
dant of the MMPs and has been found to correlate with disease
severity in TB patients [57]. The neutrophil specific matrix
metalloproteinase MMP25 degrades substrates found in fibroblasts
and may enhance the phagocytic removal of neutrophils from
inflammatory sites [58].
Conclusions
Analysis of gene-expression data is a complex process which can
be performed using many different strategies. Commonly genes
are grouped according to similar changes in expression profiles,
e.g. using non-hierarchical clustering. More recently, groups of
genes have been clustered into modules based on their shared
expression (and likely involvement) in biological processes [33].
These modular representations have become more popular in
annotating function to gene expression data. However, joint
expression of genes during certain processes/diseases does not
necessarily demonstrate functional relatedness. Related gene
expression events may be dynamic and occur in sequence rather
than simultaneously such that genes with strong functional
relations may not necessarily be detected at the same time point
in the (disease) process and therefore may not group into the same
cluster or module. The assessment of pathways and processes that
seem key in the disease process seems to be more valuable than
merely assessing the combination of genes with the highest
changes in expression levels.
Here we explored functional interactions based on known
molecular interactions (Ingenuity) and enrichment of genes in
biological pathways (GSEA) to analyze gene expression data
described in TB disease at a higher aggregation level, from an
helicopter perspective. Dominant pathways may not only serve as
biomarkers at the transcription level as such, but products from
these pathways or cellular responses induced by that particular
pathway may also be significant indicators of disease, potentially
allowing easier assessment of pathway activity in simpler tests.
Future assessments of biomarkers for vaccine-induced protection
may benefit from similar, pathway/process based analyses to allow
more powerful biomarker selection (Figure 4).
Interestingly, multiple genes affected in TB disease were
involved in more than a single pathway (Table S1, Figure 1),
emphasizing the impact of individual signaling components in
multiple pathways. Therefore, assessment of total pathway
function or at least multiple components from the same pathways
may be a more reliable measurement of such pathways than
individual markers that are functionally involved in many different
signal transduction chains.
The combined analysis of TB biomarkers of disease identified
by 8 independent studies revealed a less dominant role for the
IFNa/b related genes, but revealed a very strong involvement of
myeloid cells. In particular signaling through Pattern Recognition
Receptors, Fc receptors, fibrosis and TREM1 seemed key players
during active TB disease. These findings may be somewhat
unexpected, mostly because all profiling was performed in whole
blood or purified PBMCs and not at the site of disease. In
particular in Mtb infection, the local activation of myeloid cells
and receptors involved in pathogen recognition are expected to be
key players in the disease process, yet also systemic activation of
these pathways is emphasized by our analysis. These cells may
either traffic from the site of disease into the circulation or may
have been indirectly activated by pathogen derived products that
have entered the circulation, thus mirroring activated phagocytes
at the site of disease. It is somewhat surprising to detect a
prominent activated myeloid cell signature in the circulation,
because generally activation would occur in tissues and cells would
subsequently follow the lymphoid system to migrate towards
lymphoid organs. Apparently, during active TB disease inflam-
mation may be of such magnitude that the inflammatory site spills
over into the circulation such that activated myeloid cells can be
detected in peripheral blood (Figure 4).
In this context, the identification of TREM1 signalling is
interesting, providing a new angle for activation of monocytic cells
by Mtb. Potentially, Mtb derived molecules target this pathway, in
synergy with TLRs, to activate innate and adaptive immune
responses. Additional new leads may include pathways associated
with hematopoiesis and B cell activation. Several pathways
associated with hematopoiesis were identified by Ingenuity
pathway analysis, which may support new recent leads of
circulating hematopoietic progenitor cells during TB disease.
However, the individual genes that fit into these pathways are also
involved in myeloid cell activation and inflammation. Therefore
genes exclusively associated with hematopoiesis in particular need
to be investigated to determine the relevance of hematopoiesis in
TB disease. B cell activation in the circulation of patients with TB
disease may also require more detailed investigation, in particular
since also TB granulomas harbour B cells suggesting active
involvement with disease.
All of these pathways deserve more in-depth (functional) analysis
in TB disease and hopefully will guide exploration of new
therapeutic targets for TB disease.
Thus, our ‘helicopter’ like pathway-based analysis of multiple
independent studies reveals novel insights in the pathogenesis and
potential biomarkers of TB disease, implying a strong role for
myeloid cells in TB pathogenesis which deserves more in-depth
investigation.
Supporting Information
Table S1 All genes identified by the 8 independent
global genome-wide gene expression analyses. Genes
names are the official gene names according to gene cards (www.
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modules, functional groups according to Ingenuity and GSEA was
performed according to Tables 3 & 4.
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